Skip to main content

Market Overview

Allscripts Healthcare's Earnings Outlook


On Thursday, Allscripts Healthcare (NASDAQ: MDRX) will release its latest earnings report. Benzinga's report can help you figure out the ins and outs of the earnings release.

Earnings and Revenue

Allscripts earnings will be near 18 cents per share on sales of $523.54 million, according to analysts.

In the same quarter last year, Allscripts posted a loss of 14 cents per share on sales of $429.4 million. The analyst consensus estimate would represent a 28.57 percent increase in the company's earnings. Sales would be have grown 21.92 percent from the same quarter last year.

Here's how the company's reported EPS has stacked up against analyst estimates in the past:


Quarter Q3 2017 Q2 2017 Q1 2017 Q4 2016
EPS Estimate 0.16 0.15 0.13 0.15
EPS Actual 0.16 0.15 0.13 0.14


Stock Performance

Over the last 52-week period, shares are up 17.22 percent. Given that these returns are generally positive, long-term shareholders can relax going into this earnings release. Long-term shareholders are already enjoying 12-month gains prior to the announcement.

Analyst estimates are adjusted higher for EPS and revenues over the past 90 days. The average rating by analysts on Allscripts stock is a Neutral. The strength of this rating has maintained conviction over the past 90 days.

Conference Call

Don't be surprised to see the stock move on comments made during its conference call. Allscripts' Q4 conference call is scheduled to begin at 4:30 p.m. ET and can be accessed here.


Related Articles (MDRX)

View Comments and Join the Discussion!

Posted-In: Earnings News Previews Trading Ideas

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at